-+ 0.00%
-+ 0.00%
-+ 0.00%

BioXcel Therapeutics Plans To Submit sNDA In January Seeking FDA Approval Of IGALMI For At-Home Use In Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia.

Benzinga·01/07/2026 12:08:11
Listen to the news

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month seeking the U.S. Food and Drug Administration's (FDA) approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia.